Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

• Status: Completed
• Trial end date: 2006-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cumberland Pharmaceuticals; Theravance Biopharma Antibiotics, Inc.
• Treatments: Cloxacillin; Nafcillin; Oxacillin; Telavancin; Vancomycin

Criteria

Inclusion Criteria

• Documented S. aureus bacteremia

Exclusion Criteria

• Patients who had received or would have received more than 72 hours of potentially effective systemic antistaphylococcal therapy within 7 days prior to randomization. The following agents were considered potentially effective antistaphylococcal therapy: antistaphylococcal penicillins (including nafcillin, oxacillin, or cloxacillin), cephalosporins, fluoroquinolones, glycopeptides (including vancomycin and teicoplanin) and linezolid